Tempus is one of the world’s largest biotech companies. The company promotes health care through the practical application of artificial intelligence and machine learning in medicine. It was primarily formed by Eric Lefkofsky with the goal to cure cancer, a problem that is obviously prevalent worldwide. Now the company is expanding its treatment to other health areas such as depression and cardiology. Eric Lefkofsky has stated that it is rapidly developing in the health sector with various innovative medical solutions across many different projects. Durham’s lab: Tempus declared that it is starting a 52,000 square feet genomic sequencing lab in Durham’s Research Triangle Park of North Carolina.
It is the third such space constructed outside of Chicago. Durham’s lab helps physicians to provide customized treatments for all their patients by expanding their knowledge of genomic sequencing. It is expected to be completed in late 2021 and is projecting numbers of about 200 new staff members hired. Tempus one: Tempus ONE is the latest innovation of Tempus. According to Eric Lefkofsky, it is a device that connects physicians all across the country and permits them to talk to their database. For Eric Lefkofsky, it takes the multi-modal data, puts it through a clinical context, and helps physicians easily access their patients’ health history and conditions.
It is a physical embodiment of the Tempus database that could be placed on an office desk or in one’s pocket. Eric Lefkofsky pointed out that its portability acts as a boon for physicians to access their patients’ health records anytime at all places. Research Use Only: Tempus also declared that it is launching Research Use Only (RUO), which is an amplicon-based, next-generation sequencing evaluation for the identification of mutations from the SARS-CoV-2 virus. It helps physicians identify and treat the SARS-CoV-2 virus effectively. Tempus CEO and founder Eric Lefkofsky said that “ it is essential for Tempus to innovate and upgrade their testing potentials”.